Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5 , pK i =8.2/9.0/9.1/ Appearance:Solid IC50& Target:pKi: 8.2 (sst1), 9.0 (sst2), 9.1 (sst3), In Vitro:Pasireotide ditrifluoroacetate exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1/2/3/4/5, pK i =8.2/9.0/9.1/ In Vivo:Pasireotide ditrifluoroacetate (160mg/kg/mouth; s.c. for 4 months) significantly decreases the serum insulin, increases serum glucose, reduces the tumor size and increases apoptosis in Pdx1-Cre. Pasireotide ditrifluoroacetate (2-50 μg/kg; s.c. twice Biological Activity:Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5 , pK i =8.2/9.0/9.1/
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
Pasireotide ditrifluoroacetate
CAS number：unknown molecular formula：C62H68F6N10O13
overview
compound introduction
Specs
| Chinese alias | 帕瑞肽二三氟乙酸酯 | ||
| English alias | - | ||
| CAS number | unknown | molecular formula | C62H68F6N10O13 |
| molecular weight | 1275.25 g/mol | Exact mass | ≥99% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
